|
Variable
| |
Univariate analysis
|
Multivariate analysis
|
|---|
| |
OR (95% CI)
|
P
|
OR (95% CI)
|
P
|
|---|
|
Age (year)
| |
0.994 (0.963–1.027)
|
0.719
| | |
|
Sex
|
(Female)
|
0.570 (0.203–1.603)
|
0.287
| | |
|
Body mass index (kg/m2)
| |
0.885 (0.783–1.000)
|
0.050
| | |
|
ECOG PS
|
(1 vs. 0)
|
3.000 (0.627–14.358)
|
0.169
| | |
|
Etiology
|
HCV vs. nonviral
|
0.440 (0.167–1.16)
|
0.097
|
0.612 (0.179–2.088)
|
0.433
|
| |
HBV vs. nonviral
|
0.200 (0.055–0.722)
|
0.014
|
0.133 (0.027–0.666)
|
0.014
|
|
Ascites
|
2 vs. 1
|
2.333 (0.473–11.506)
|
0.298
| | |
|
Platelet (×103/μL)
| |
1.006 (1.001–1.011)
|
0.017
|
1.005 (0.999–1.011)
|
0.103
|
|
Creatinine (mg/dL)
| |
1.115 (0.529–2.348)
|
0.775
| | |
|
Albumin (g/dL)
| |
1.168 (0.488–2.794)
|
0.727
| | |
|
Total bilirubin (mg/dL)
| |
1.541 (0.698–3.405)
|
0.285
| | |
|
Prothrombin time (INR)
| |
6.922 (0.164–291.871)
|
0.311
| | |
|
MELD
| |
1.208 (0.937–1.558)
|
0.145
| | |
|
Macrovascular invasion
| |
1.615 (0.71–3.677)
|
0.253
| | |
|
Extrahepatic spread
| |
1.506 (0.708–3.205)
|
0.288
| | |
|
BCLC stage
|
B vs. A
|
1.000 (0.315–3.174)
|
1.000
|
0.808 (0.203–3.224)
|
0.763
|
| |
C vs. A
|
2.895 (1.002–8.364)
|
0.050
|
3.476 (0.987–12.243)
|
0.052
|
|
Log AFP (ng/dL)
| |
1.013 (0.779–1.317)
|
0.925
| | |
|
Log PIVKA-II (mAU/mL)
| |
1.989 (1.359–2.911)
|
< 0.001
|
1.724 (1.124–2.644)
|
0.013
|
|
Log Angiopoietin 2 (ng/mL)
| |
3.754 (0.534–26.374)
|
0.183
| | |
|
Log CD117 (ng/mL)
| |
2.895 (0.612–13.687)
|
0.18
| | |
|
bFGF (pg/mL)
| |
1.321 (1.092–1.598)
|
0.004
|
1.326 (1.077–1.634)
|
0.008
|
|
Log HGF (pg/mL)
| |
16.534 (1.275–214.349)
|
0.032
|
23.438 (0.750–732.109)
|
0.072
|
|
LOXL2 (ng/mL)
| |
0.769 (0.533–1.11)
|
0.160
| | |
|
Log sVEGFR1 (ng/mL)
| |
0.272 (0.047–1.592)
|
0.149
| | |
|
AAR
| |
1.373 (0.84–2.246)
|
0.206
| | |
|
APRI
| |
0.971 (0.718–1.314)
|
0.85
| | |
|
FIB4
| |
0.926 (0.842–1.02)
|
0.12
| | |
|
Lok index
| |
0.722 (0.154–3.386)
|
0.68
| | |
|
P2/MS
| |
1.004 (0.998–1.01)
|
0.179
| | |
- Abbreviations: OR odds ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, MELD model for end-stage liver disease, INR international normalized ratio, AFP alpha-fetoprotein, PIVKA-II protein induced by vitamin K absence-II, Ang2 angiopoietin-2, bFGF basic fibroblast growth factor, HGF hepatocyte growth factor, LOXL2 lysyl oxidase-like 2, PDGFRb platelet-derived growth factor receptor β, sVEGFR1 soluble vascular endothelial growth factor receptor-1, AAR aspartate aminotransferase/alanine aminotransferase ratio, APRI aspartate aminotransferase to platelet ratio index, FIB-4 fibrosis 4
